中航電測(300114.SZ):正籌劃收購成飛集團100%股權、明起停牌
格隆匯1月11日丨中航電測(300114.SZ)公佈,公司正在籌劃發行股份購買資產事項,此次交易的標的資產初步確定為成都飛機工業(集團)有限責任公司(“成飛集團”)的100%股權。此次交易前,中國航空工業集團有限公司(“航空工業集團”)持有成飛集團100%股份,為成飛集團的控股股東、實際控制人。
根據深圳證券交易所的相關規定,經公司申請,公司股票自2023年1月12日開市時起開始停牌。
公司預計在不超過10個交易日的時間內披露此次交易方案,即在2023年2月2日前按照《公開發行證券的公司信息披露內容與格式準則第26號——上市公司重大資產重組》的要求披露相關信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.